Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe, 4 ML
Skip image gallery
Image/color similar
Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe is a medical device indicated for the relief of pain and improvement of the function of arthritic joints and for the conservative treatment of meniscus lesions in the knee.
€339.50
Content:
4 Milliliter
(€84.88 / 1 Milliliter)
(May vary by country)
Ready to ship in 1-3 working days ⁴
Product number:
RA5848232
Milliliter:
Manufacturer:
Fidia Pharma Austria GmbH
Traungasse 14, 4.Stock,
1030 Wien,
Österreich
Product information "Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe"
The Hymovis HYADD® 4 ONE 32 mg/4 ml pre-filled syringe is a medical device indicated for the relief of pain and improvement of function in arthritic joints, and for the conservative treatment of meniscal lesions in the knee.
The patented hyaluronic acid molecule in Hymovis® (HYADD®4) is a new development and is unlike any other hyaluronic acid on the market:
- Hymovis® combines the beneficial properties of low- and high-molecular-weight hyaluronic acid without inheriting their disadvantages.
- As a low-molecular-weight HA, it has better access to the CD44 receptor, which is responsible for the synthesis of the body’s own HA 13
- Thanks to the biochemically modified molecule (HYADD4), Hymovis is more viscous and provides better lubrication than even cross-linked HA 6
- Despite its high viscosity within the joint, Hymovis is as easy to inject as low-molecular-weight HA
What sets Hymovis® apart
Unique molecule:
- Hymovis® has a unique structure: the biochemical modification of the hyaluronic acid molecule results in a new product.
- In stress tests, it has been shown to be more resilient than cross-linked HA.1-3
Long-lasting lubrication in the joint:
- In comparison, Hymovis® achieves a better lubricating effect than cross-linked HA and, consequently, a better clinical outcome.6
- Promotes hyaluronic acid synthesis: High biological activity can stimulate endogenous HA synthesis.9
Positive effect on cartilage structure:
- Hymovis® protects intra-articular tissue and thus promotes the metabolism of the cartilage matrix.7
- An increase in cartilage volume and thickness in the lateral knee compartment following treatment with Hymovis® was demonstrated by MRI.
- Reduced cartilage catabolism and enhanced collagen synthesis have been demonstrated by biological markers.
High load-bearing capacity:
- Reversible interactions prevent the 3D structure from breaking down under highloads4,5
- Long-lasting retention in the joint: Significantly longer stability and retention time in the joint compared with cross-linked hyaluronic acids.8
- Excellent shock absorption:The high elasticity of the molecules ensures strongpressure absorption⁴,⁵
In which cases can I use Hymovis® and what effect does it have on patients?
Due to its molecular structure, which ensures high load-bearing capacity, Hymovis® is particularly suitable for mobile, active people and competitive athletes with:
- Osteoarthritis of the knee joint (gonarthrosis) Osteoarthritis of the shoulder joint Osteoarthritis of the thumb joint (rhizarthrosis)
- Osteoarthritis of the hip joint (coxarthrosis) Osteoarthritis of the ankle joint
- Osteoarthritis in other joints Meniscus damage
How does Hymovis® work?
- The degenerative and inflammatory processes that occur in osteoarthritis alter both the hyaluronic acid (HA) concentration (a reduction in concentration) and the quality of hyaluronic acid (a reduction in molecular weight) in the synovial fluid, and progressively destroy the surface layer of the articular cartilage.
- To counteract these processes, a treatment for osteoarthritis involving intra-articular viscosupplementation with exogenous hyaluronic acid was developed. Viscosupplementation with hyaluronic acid improves the mechanics of joint function; the hyaluronic acid acts as a shock absorber and lubricant. Furthermore, it can produce long-term effects by stimulating the body’s own synthesis of hyaluronic acid.
- In this way, pain can be significantly reduced and the further progression of osteoarthritis slowed down.2,5,6 Hyaluronic acid may also help to reduce an increased need for cortisone.1
- Hymovis® differs from all other hyaluronic acid products due to its unique structure. The HA molecule has been optimised with a hydrophobic hexadecylamide side chain. In the hydrophilic environment of the joint space, the Hymovis molecules thus form a network known as the MObile REticulum (MO.RE® technology).
- Cross-linked hyaluronic acids consist of rigid bonds between the molecules, which break when the pressure becomes too great. Modifications to the hyaluronic acid molecule in Hymovis®, on the other hand, ensure that, due to reversible hydrophobic interactions, it can repeatedly reassemble itself into a stabilising network even under high pressure.4,5
- The molecule (HYADD®4) in Hymovis® therefore possesses shape memory. This means that it reverts to its original shape even after repeated impact or tensile movements. This results in numerous positive clinical effects for your patients, which you will find summarised under ‘Features’. As a result, the entire molecule remains intact for longer and can maintain its highly viscous structure. Rigid cross-links, as found in all other HA products – whether linear or cross-linked – break down sooner under the same pressure conditions and lose their viscous structure.
1 Benazzo F, Lovato M. OsteoArtrosi.eu 2013; 3: 8–12. 2 Zorzi Z et al. OsteoArtrosi.eu 2013; 3: 13–16. 3 Pavelka K et al. Osteoarthritis Cartilage 2010, vol. 18 no. 2 Suppl.4 Finelli I et al. Biorheology, 2011; 48 (5): 263. 5 Finelli I et al. Macromol Biosci 2009; 9: 646–653. 6 Bonnevie et al. PLoS One 2019;14(5):e0216702. 7 Henrotin Y et al. BMC Musculoskeletal Disorders 2019;20(1):293. 8 Data on file – enquiries to: medical(at)fidiapharma.de. 9 Hymovis® prescribing information, as at December 2015. 10 Castagna A et al. OsteoArtrosi.eu · 2013; 3: 17–20. 11 Bannuru RR et al. Osteoarthritis and Cartilage Volume 27, Issue 11, November 2019: 1578–1589. 12 DGOOC guideline: https://www.awmf.org/leitlinien/detail/ll/033-004.html. 13 Gosh P et al. Semin Arthritis Rheum. August 2002;32(1):10–37.
Dosage form
Pre-filled syringe
Administration
- Two appointments are sufficient for your patients to receive Hymovis®: osteoarthritis: 2 injections one week apart; meniscal lesions: 2 injections two weeks apart.
- Notes: Administration must only be carried out by qualified doctors. Please follow the instructions for use.
Ingredients
- Active ingredient: Hyadd4 (sodium hyaluronate hexadecylamide), 32 mg/4 ml.
- Other ingredients: sodium chloride, disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, water for injections.
| ML: | 4 |
|---|
Read more
No reviews found. Share your insights with others.
Warnings - Hymovis HYADD® 4 ONE 32 mg/4 ml prefilled syringe
Instructions for use
Product recommendations for you